Newron Pharmaceuticals Secures Up to EUR 15 Million in Funding Through New Share Issuance

Newron Pharmaceuticals S.p.A. ("Newron"), a leader in the development of treatments for central and peripheral nervous system diseases, has announced a significant financial development on March 14, 2024. The company declared a subscription agreement with an institutional investor, aiming to subscribe to up to 2.05 million of its newly issued shares, potentially raising up to EUR 15 million.

With an initial subscription of 750,000 new shares at EUR 7.33 per share, Newron expects to receive around EUR 5.5 million. The agreement also gives the fund the option to subscribe to an additional 1.3 million shares until January 31, 2025, based on a predetermined pricing formula. This capital increase aligns with the authorization from Newron’s shareholders in 2018 and the subsequent approval by its board in 2023.

Roberto Galli, Newron’s CFO, highlighted the investment as an endorsement of the company’s strategy to innovate in the CNS therapy domain. He expressed optimism that the funds raised would significantly support the company's pipeline developments beyond pivotal milestones. The initial new shares are set to be listed on the SIX Swiss Exchange and the Düsseldorf Stock Exchange's Primärmarkt, as well as traded on the Frankfurt Stock Exchange (Xetra), around March 20, 2024.